The reference standards will support CareDx's solid organ transplant injury monitoring diagnostic tests and be integrated into CLIA laboratory testing.
The firm will discontinue its SensiGene Fetal RHD test.
If CareDx successfully commercializes its cfDNA tests, they would be the firm's first products since AlloMap launched in 2005.
The molecular diagnostics firm beat the consensus Wall Street estimate on the top line but missed it on the bottom line.
The company is developing liquid biopsy tests to detect disease recurrence and drug resistance, but does not yet have a specific plan for its first commercial assay.
Royalty income drove the year-over-year revenue growth, but the firm still fell short of the consensus Wall Street estimate on the bottom line.
The company is embarking on a study of up to 2,000 patients to compare its tissue-based targeted sequencing assay with its cell-free DNA test.
Clinical applications for the approach are already at hand, and are poised to expand as companies solidify the clinical validity and utility data behind their platforms.
Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.
The company said it is shifting focus from demonstrating clinical validity to proving its test can improve patient care and outcomes.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.